Discontinued — last reported Q4 '22
Revolution Medicines, Inc. Interest Income decreased by 8.4% to $19.51M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 21.7%, from $24.92M to $19.51M. Over 4 years (FY 2021 to FY 2025), Interest Income shows an upward trend with a 214.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher interest income suggests a strong cash position or a favorable interest rate environment for the company's investments.
Interest income is the revenue earned from cash deposits, marketable securities, and other interest-bearing investments....
Varies based on cash management strategies; companies with large cash piles will report higher interest income than those with high debt.
interest_income| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $236.00K | $223.00K | $237.00K | $302.00K | $867.00K | $2.91M | $5.08M | $7.06M | $10.50M | $10.95M | $18.98M | $23.76M | $21.49M | $20.41M | $21.23M | $24.92M | $22.40M | $22.08M | $21.29M | $19.51M |
| QoQ Change | — | -5.5% | +6.3% | +27.4% | +187.1% | +235.3% | +74.7% | +39.0% | +48.7% | +4.3% | +73.4% | +25.2% | -9.6% | -5.0% | +4.0% | +17.4% | -10.1% | -1.4% | -3.6% | -8.4% |
| YoY Change | — | — | — | — | +267.4% | >999% | >999% | >999% | >999% | +276.6% | +273.7% | +236.6% | +104.7% | +86.5% | +11.8% | +4.9% | +4.3% | +8.2% | +0.3% | -21.7% |